Bemnifosbuvir Hemisulfate

DRUG3 trials

Sponsors

Atea Pharmaceuticals Inc., Atea Pharmaceuticals Inc., Atea Pharmaceuticals Inc., ATEA Pharmaceuticals

Conditions

COVID-19Chronic Hepatitis C Virus (HCV) InfectionRespiratory

Phase 2

A Phase 2, Open-Label Study to Assess the Safety and Efficacy of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

CompletedCTIS2023-504566-28-00

Atea Pharmaceuticals Inc.Chronic Hepatitis C Virus (HCV) Infection

Start: 2023-05-19End: 2025-01-28Target: 39Updated: 2024-04-22

Phase 3

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

RecruitingPACTR202304814474622

ATEA PharmaceuticalsRespiratory

Start: 2022-11-25Target: 1500Updated: 2026-01-27

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Bemnifosbuvir in High-Risk Outpatients with COVID-19

CompletedCTIS2023-504540-33-00

Atea Pharmaceuticals Inc., Atea Pharmaceuticals Inc.COVID-19

Start: 2023-03-06End: 2024-05-06Target: 354Updated: 2024-04-09